Aspirin moderates the association between cardiovascular risk, brain white matter hyperintensity total lesion volume

Mina Khezrian1, Jennifer M J Waymont1, Phyo K Myint2

  • 1Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Maturitas
|February 2, 2020
PubMed

Insights

Low-dose aspirin use moderates the negative impact of white matter hyperintensity (WMH) burden on cognitive function in older adults. Aspirin users showed a stronger link between WMH and cognition than non-users.

Area of Science:

  • Neurology
  • Gerontology
  • Cardiovascular Medicine

Background:

  • Cardiovascular risk is linked to cognitive decline via brain pathology like white matter hyperintensity (WMH).
  • Low-dose aspirin is commonly used to prevent vascular events.

Purpose of the Study:

  • To investigate how aspirin use affects the relationship between cardiovascular risk, WMH burden, and cognitive function.
  • To determine if aspirin use modifies the impact of WMH on cognition.

Main Methods:

  • Study included 318 dementia-free adults (aged 67-71), with 239 undergoing brain MRI.
  • White matter hyperintensity total lesion volumes (TLV) were quantified using automated segmentation.
  • Cardiovascular risk was assessed using the ASSIGN score, and cognitive ability by processing speed tests.

Main Results:

  • Sixty-eight participants (47.1% male, mean age 68.8) reported aspirin use.
  • Aspirin users showed a significant negative association between WMH TLV and cognition (β = -0.43, p < 0.001).
  • In non-users, only cardiovascular risk predicted poorer cognition (β = -0.17, p = 0.001).

Conclusions:

  • Aspirin use moderates the detrimental effect of WMH burden on cognitive function.
  • Incorporating WMH burden alongside cardiovascular risk may enhance cognitive decline prediction in older aspirin users.
Abstract

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
147
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279
Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
522